Page 25 - Cipla

Concerns aggravate for Cipla, Alkem

More worries for Alkem, as its Daman plant, which is under scanner, is crucial for US growth

Cipla falls on heavy volumes

The stock dipped 6% to Rs 562 in intra-day trade on media reports that the USFDA inspected the company's Goa facility.

Drug firms facing challenging times due to price control: Cipla

Tightening of new product registration procedures also impacting industry

Cipla gets USFDA nod for generic anti-depressant drug

Company's shares were today trading at Rs 570.25 per scrip in the afternoon trade on BSE, up 0.54% from its previous close

Cipla, Godrej recognised in Fortune Change the World list

Fortune lauded Cipla for driving prices down for much-needed medications

Street positive on Cipla despite weak results

Base business growth in the US, and bottoming out of operating-profit margins are key positives

Cipla gains post June quarter results

The stock was up 5% at Rs 540 on the NSE, as compared to 0.57% fall in the Nifty 50 index at 12:49 pm.

Cipla's net profit dips 44%, announces new CEO

Overall revenue of Cipla falls 6%; international business drops 14%

Cipla first quarter profit lags estimates; names new CEO

Cipla's April-June net profit was 3.65 billion rupees, compared with 6.49 billion rupees a year earlier

Cipla appoints Kedar Upadhye as Global CFO

Earlier, he has worked with Pepsi India and Thermax Group

Cipla told to deposit Rs 175 crore in drug overcharging case

The case pertains to 2003 when Cipla received a demand notice from the National Pharmaceutical Pricing Authority for alleged overcharging of drugs covered under price cap

Cipla to set up biotech plant in South Africa

Cipla Biotech, a subsidiary of the company, will construct the plant at a special economic zone in Durban and will commence production in 2018

Cipla: Short-term pain despite strong base

Cipla has missed analysts' expectation by 30 per cent at the EBITDA level for the year

Cipla hits 52-week low on disappointing Q4 results

The stock dipped 7% to Rs 460, also its 52-week low on the BSE.

Cipla net profit declines 69% due to one-off expenses

Cipla's Ebitda also declined nearly 57% to Rs 219 crore

Cipla Q4 net drops 69% to Rs 81 cr

Consolidated total income from operations of the company stood at Rs 3,266.54 crore for the quarter under consideration

Cipla bets big on consumer health segment

Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market

Cipla invests additional $ 3 million in US's Chase Pharmaceuticals

Company in May 2014 had invested $1.5 million to acquire 14.6% stake in Chase Pharmaceuticals

Cipla transfers consumer healthcare business to subsidiary

Shares of Cipla today closed at Rs 517.50 per scrip on BSE, up 0.49% from the previous close

Cipla completes $550 million acquisition of 2 US generic drug companies

The acquisition of InvaGen and Exelan will boost Cipla's US business which currently accounts for 8% of its revenue